About: Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient
Creator	Wang, Pengfei Wang, Xinquan Zhang, Linqi Zhang, Senyan Zhou, Panpan Deng, Yao Niu, Peihua Tan, Wenjie Wang, Wenling Huang, Baoying Zhou, Jianfang Qin, Kun
Source	Medline; PMC
abstract	BACKGROUND: The Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection with a high (~35%) mortality rate. Neutralizing antibodies targeting the spike of MERS-CoV have been shown to be a therapeutic option for treatment of lethal disease. METHODS: We describe the germline diversity and neutralizing activity of 13 potent human monoclonal antibodies (mAbs) that target the MERS-CoV spike (S) protein. Biological functions were assessed by live MERS-CoV, pseudotype particle and its variants, and structural basis was also determined by crystallographic analysis. RESULTS: Of the 13 mAbs displaying strong neutralizing activity against MERS-CoV, two with the immunoglobulin heavy-chain variable region (IGHV)1-69-derived heavy chain (named MERS-GD27 and MERS-GD33) showed the most potent neutralizing activity against pseudotyped and live MERS-CoV in vitro. Mutagenesis analysis suggested that MERS-GD27 and MERS-GD33 recognized distinct regions in S glycoproteins, and the combination of 2 mAbs demonstrated a synergistic effect in neutralization against pseudotyped MERS-CoV. The structural basis of MERS-GD27 neutralization and recognition revealed that its epitope almost completely overlapped with the receptor-binding site. CONCLUSIONS: Our data provide new insights into the specific antibody repertoires and the molecular determinants of neutralization during natural MERS-CoV infection in humans. This finding supports additional efforts to design and develop novel therapies to combat MERS-CoV infections in humans.
has issue date	2018-10-15(xsd:dateTime)
bibo:doi	10.1093/infdis/jiy311
bibo:pmid	29846635
has license	no-cc
sha1sum (hex)	ab8ecae5d2918216407630df1efa44a9e77ed109
schema:url	https://doi.org/10.1093/infdis/jiy311
resource representing a document's title	Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient
has PubMed Central identifier	PMC7107445
has PubMed identifier	29846635
schema:publication	J Infect Dis
resource representing a document's body	covid:ab8ecae5d2918216407630df1efa44a9e77ed109#body_text
is schema:about of	named entity 'DISEASE' named entity 'MORTALITY RATE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'CAUSES' named entity 'BACKGROUND' named entity 'MERS-COV' named entity 'TARGETING' named entity 'HUMAN' named entity 'RECOVERED' named entity 'OPTION' named entity 'SPIKE' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'PATIENT' named entity 'NEUTRALIZING ANTIBODY' named entity 'HIGH' named entity 'SEVERE' named entity 'RESPIRATORY INFECTION' named entity 'LETHAL' named entity 'HAVE' named entity 'TREATMENT' named entity 'THERAPEUTIC' covid:arg/ab8ecae5d2918216407630df1efa44a9e77ed109 named entity 'therapeutic' named entity 'clinical testing' named entity 'RBD' named entity 'light chain' named entity 'gene' named entity 'mAb' named entity 'antiviral' named entity 'synergistic' named entity '293T cells' named entity 'protein' named entity 'DPP4' named entity 'immunoglobulin' named entity 'mortality rate' named entity 'protein' named entity 'infection' named entity 'RBD' named entity 'peripheral blood mononuclear cells' named entity 'MERS-CoV' named entity 'B-cell' named entity 'Shanghai' named entity 'affinity maturation' named entity 'genetically distinct' named entity 'kidney' named entity 'mAbs' named entity 'half maximal inhibitory concentration' named entity 'epitopes' named entity 'binding activity' named entity 'immunoglobulin' named entity 'epitopes' named entity 'MERS-CoV' named entity 'HEK' named entity 'IGHV' named entity 'RBD' named entity 'MERS-CoV' named entity 'Sequencing data' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'mortality rate' named entity 'MERS-CoV' named entity 'Repertoires' named entity 'ED95' named entity 'mAbs' named entity 'potency' named entity 'germline' named entity 'amino acid' named entity 'MERS-CoV' named entity 'mAbs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software